New Weight-Loss drug CPX101 enters early human testing
NCT ID NCT06545162
First seen Apr 17, 2026 · Last updated May 01, 2026 · Updated 1 time
Summary
This early-stage study tested a new drug called CPX101 in 72 healthy volunteers and overweight or obese patients. The main goal was to see if the drug is safe and tolerable, and to measure how it moves through the body. Researchers also looked at whether multiple doses could help with weight loss, but this was a preliminary exploration.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Friendship Hospital
Beijing, Beijing Municipality, 100000, China
-
Beijing Luhe hospital
Beijing, Beijing Municipality, 100000, China
-
Beijing hospital
Beijing, Beijing Municipality, 100000, China
Conditions
Explore the condition pages connected to this study.